about
Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trialsDual-mode imaging and therapeutic effects of drug-loaded phase-transition nanoparticles combined with near-infrared laser and low-intensity ultrasound on ovarian cancerDecreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell
P2860
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Advances in ovarian cancer therapy.
@en
Advances in ovarian cancer therapy.
@nl
type
label
Advances in ovarian cancer therapy.
@en
Advances in ovarian cancer therapy.
@nl
prefLabel
Advances in ovarian cancer therapy.
@en
Advances in ovarian cancer therapy.
@nl
P2860
P50
P1476
Advances in ovarian cancer therapy.
@en
P2860
P2888
P356
10.1007/S00280-017-3501-8
P5008
P577
2017-12-16T00:00:00Z
2018-01-01T00:00:00Z